<DOC>
	<DOCNO>NCT02032095</DOCNO>
	<brief_summary>It intend examine safety efficacy desensitization therapy GB-0998 ( intravenous immunoglobulin ) anti-donor antibody positive recipient need pre-transplant desensitization . Patients positive FCXM-T performing twice double filtration plasmapheresis ( DFPP ) therapy receive GB-0998 1g/kg/day four day .</brief_summary>
	<brief_title>The Desensitization Therapy With GB-0998 Anti-donor Antibody-positive Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Patients stage 4 5 CKD classification . Of patient want livingdonor kidney transplant ABO blood type compatible , patient positive FCXMT negative CDCT donor . Patients positive FCXMT performing twice DFPP therapy Patients take continue immunosuppressive drug steroid within 4 week obtain informed consent . Patients IVIG therapy , plasmapheresis therapy within 12 week inform consent . Patients Rituximab within 6 month inform consent . Patients undergone splenectomy . Patients severe hepatic disorder severe heart disorder . Patients receive treatment malignancy . Patients high risk thromboembolism . Patients history shock hypersensitivity GB0998 . Patients hereditary fructose intolerance IgA deficiency . Patients pregnant probably pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>IVIG</keyword>
	<keyword>Renal transplantation</keyword>
	<keyword>desensitization</keyword>
</DOC>